SCHEMBL3078552

SCHEMBL3078552

COc1ccc(Cc2noc3ccc[c]c23)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.41
RAB9A P51151 5/20 0.41
SMN1; SMN2 Q16637 5/20 0.41
NPC1 O15118 4/20 0.41
L3MBTL1 Q9Y468 3/20 0.41
TDP1 Q9NUW8 3/20 0.41
PKM P14618 1/20 0.38
MAPK1 P28482 2/20 0.38
MAPT P10636 2/20 0.38
MAOB P27338 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ALOX5 P09917 1/20 0.38
KDR P35968 2/20 0.37
TSHR P16473 2/20 0.37
MEN1 O00255 1/20 0.37
HTT P42858 1/20 0.37
KMT2A Q03164 1/20 0.37
ALOX15 P16050 1/20 0.37
VKORC1 Q9BQB6 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3084411 0.85 LMNA (0.31) RAB9ASMN1; SMN2NPC1MAPTLMNA
SCHEMBL3094887 0.81 VKORC1 (0.36) RAB9ANPC1TSHRMEN1KMT2A
SCHEMBL3082999 0.81 HTR1D (0.34) TDP1
SCHEMBL9589093 0.75 CA12 (0.33) SMN1; SMN2MAOBLMNA
SCHEMBL3090836 0.73 LTA4H (0.41) LTA4HRAB9ASMN1; SMN2NPC1L3MBTL1
SCHEMBL3091127 0.73 ALDH1A1 (0.44) LTA4HRAB9ASMN1; SMN2NPC1MAPT
SCHEMBL3089243 0.69 LTA4H (0.46) LTA4HRAB9ASMN1; SMN2NPC1L3MBTL1
SCHEMBL2357024 0.66 LTA4H (0.50) LTA4HRAB9ASMN1; SMN2NPC1L3MBTL1
SCHEMBL4590437 0.66 BRD4 (0.33)
SCHEMBL542478 0.65 LTA4H (0.58) LTA4HRAB9ASMN1; SMN2NPC1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207134-B2 Fused ring spiroketal derivative and use thereof as anti-diabetic drug CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-06-26 US disclosed
US-20100234609-A1 FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-09-16 US disclosed
EP-2048152-A1 FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS DRUG FOR TREATING DIABETES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-04-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234609-A1 FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG REN, WNK1, GCKR LTA4H 2233/4885RAB9A 1447/4885SMN1; SMN2 3852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.